Stock Price
2.17
Daily Change
-0.18 -7.66%
Monthly
-3.98%
Yearly
69.53%
Q2 Forecast
2.13

Galectin Therapeutics reported $-12.37M in Net Income for its fiscal quarter ending in June of 2024.





Net Income Change Date
AbbVie USD 695M 1.12B Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Galectin Therapeutics USD -12.37M 880K Jun/2024
Gilead Sciences USD 2.02B 162M Mar/2026
Immunic USD -19.3M 6.28M Dec/2025
Incyte USD 303.33M 4.05M Mar/2026
Merck USD -4.24B 7.2B Mar/2026